Novel Liver-targeted conjugates of Glycogen Phosphorylase Inhibitor PSN-357 for the Treatment of Diabetes: Design, Synthesis, Pharmacokinetic and Pharmacological Evaluations

PSN-357, an effective glycogen phosphorylase (GP) inhibitor for the treatment for type 2 diabetics, is hampered in its clinical use by the poor selectivity between the GP isoforms in liver and in skeletal muscle. In this study, by the introduction of cholic acid, 9 novel potent and liver-targeted co...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Liying, Song, Chengjun, Miao, Guangxin, Zhao, Lianzhi, Yan, Zhiwei, Li, Jing, Wang, Youde
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5320518/
https://www.ncbi.nlm.nih.gov/pubmed/28225016
http://dx.doi.org/10.1038/srep42251

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5320518/
https://www.ncbi.nlm.nih.gov/pubmed/28225016
http://dx.doi.org/10.1038/srep42251

Ejemplares similares